Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study
- PMID: 40424329
- DOI: 10.1161/CIRCULATIONAHA.124.072636
Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study
Keywords: NPR1 agonist; XXB750; blood pressure; cGMP; natriuretic peptide system.
Conflict of interest statement
Drs He, Wu, Markiewicz, Healy, Yan, Kulmatycki, Kinhikar, Yates, Hinder, Russo, and O’Donnell are employees of Novartis. Dr Diener was an employee of Novartis until January 2020. Dr Zhang was an employee of Novartis until April 2024. A. Dr Serra-Roma was an employee of Novartis until October 2024. Dr Nguyen is an employee of Altasciences Clinical, which received research support from Novartis for the conduct of this study.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
